Atara Biotherapeutics (ATRA) Interest Coverage Ratio (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Interest Coverage Ratio came in at 4.06 in Q1 2026, down 143.3% YoY from 9.37 in Q1 2025, and up 96.36% on a QoQ basis from 111.43 in Q4 2025.
Atara Biotherapeutics (ATRA) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Interest Coverage Ratio data on file, last reported at 4.06 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 143.3% year-over-year to 4.06 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.61 (up 50.9% YoY) and the FY2025 annual result came in at 0.1, up 101.94% from the prior year.
- Interest Coverage Ratio advanced to 4.06 in Q1 2026, from 111.43 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 9.37 in Q1 2025 to a low of 158.38 in Q1 2022.
- A 5-year average of 30.93 and a median of 7.83 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio plunged 5562.65% — and 2025, when it jumped 219.8%.
- Tracing ATRA's Interest Coverage Ratio over 5 years: stood at 5.74 in 2022, then tumbled by 788.35% to 50.99 in 2023, then soared by 94.19% to 2.96 in 2024, then tumbled by 3660.46% to 111.43 in 2025, then surged by 96.36% to 4.06 in 2026.
- The last three Interest Coverage Ratio figures came in at 4.06 (Q1 2026), 111.43 (Q4 2025), and 0.57 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | -24.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.36 |
| Mar 31, 2026 | -4.06 |
| Dec 31, 2025 | -111.43 |
| Sep 30, 2025 | -0.57 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 9.37 |
| Dec 31, 2024 | -2.96 |
| Sep 30, 2024 | -18.39 |
| Jun 30, 2024 | -14.45 |
| Mar 31, 2024 | -7.83 |
| Dec 31, 2023 | -50.99 |
| Sep 30, 2023 | -49.90 |
| Jun 30, 2023 | -51.82 |
| Mar 31, 2023 | -56.15 |
| Dec 31, 2022 | -5.74 |
| Sep 30, 2022 | -0.88 |
| Jun 30, 2022 | -1.78 |
| Mar 31, 2022 | -158.38 |
| Dec 31, 2021 | -76.37 |
| Sep 30, 2021 | -3.66 |